Einzeltreffer — DigiBib

Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Titel:	Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.
Autor/in / Beteiligte Person:	Zhang, ZY ; Li, C ; Zug, C ; Schluesener, HJ
Link:	Zum Volltext
Zeitschrift:	PloS one, Jg. 9 (2014-08-07), Heft 8, S. e104616
Veröffentlichung:	San Francisco, CA : Public Library of Science, 2014
Medientyp:	academicJournal
ISSN:	1932-6203 (electronic)
DOI:	10.1371/journal.pone.0104616
Schlagwort:	Alzheimer Disease genetics Alzheimer Disease metabolism Alzheimer Disease pathology Amyloid beta-Protein Precursor genetics Animals Disease Models, Animal Female Humans Mice Mice, Transgenic Transforming Growth Factor beta1 genetics Alzheimer Disease drug therapy Amyloid beta-Protein Precursor biosynthesis Behavior, Animal drug effects Flavonoids pharmacology Transforming Growth Factor beta1 metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [PLoS One] 2014 Aug 07; Vol. 9 (8), pp. e104616. <i>Date of Electronic Publication: </i>2014 Aug 07 (<i>Print Publication: </i>2014). MeSH Terms: Alzheimer Disease / drug therapy ; Amyloid beta-Protein Precursor / biosynthesis ; Behavior, Animal / drug effects ; Flavonoids / pharmacology ; Transforming Growth Factor beta1 / *metabolism ; Alzheimer Disease / genetics ; Alzheimer Disease / metabolism ; Alzheimer Disease / pathology ; Amyloid beta-Protein Precursor / genetics ; Animals ; Disease Models, Animal ; Female ; Humans ; Mice ; Mice, Transgenic ; Transforming Growth Factor beta1 / genetics References: Drugs. 2011 Oct 22;71(15):2031-65. (PMID: 21985169) ; Neurobiol Aging. 2000 May-Jun;21(3):383-421. (PMID: 10858586) ; Nat Med. 2001 May;7(5):612-8. (PMID: 11329064) ; J Ethnopharmacol. 2011 Dec 8;138(3):731-6. (PMID: 22027446) ; Biochimie. 2012 Dec;94(12):2514-22. (PMID: 22796380) ; Psychopharmacology (Berl). 2010 Oct;212(2):181-91. (PMID: 20640406) ; Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8025-30. (PMID: 12048239) ; PLoS One. 2010 Mar 22;5(3):e9764. (PMID: 20339537) ; Behav Brain Res. 2011 Jan 1;216(1):408-13. (PMID: 20804789) ; Clin Exp Pharmacol Physiol. 2007 Aug;34(8):792-5. (PMID: 17600559) ; Stroke. 2005 Apr;36(4):847-52. (PMID: 15746452) ; Curr Alzheimer Res. 2006 Jul;3(3):191-5. (PMID: 16842094) ; Am J Pathol. 2000 Jan;156(1):139-50. (PMID: 10623661) ; Neuroreport. 2009 Nov 25;20(17):1564-7. (PMID: 19858766) ; J Biol Chem. 2003 May 16;278(20):18408-18. (PMID: 12626500) ; Science. 2002 Oct 25;298(5594):789-91. (PMID: 12399581) ; Life Sci. 2007 Aug 16;81(10):832-40. (PMID: 17764702) ; Neuropharmacology. 2010 Mar-Apr;58(4-5):774-83. (PMID: 20035772) ; Brain Res Mol Brain Res. 1993 Aug;19(3):251-6. (PMID: 8412571) ; Behav Brain Res. 2011 Jan 1;216(1):77-83. (PMID: 20655336) ; Curr Psychiatry Rep. 2010 Feb;12(1):39-45. (PMID: 20425309) ; Stroke. 2002 Nov;33(11):2675-80. (PMID: 12411660) ; J Cell Physiol. 2013 Mar;228(3):513-21. (PMID: 22777826) ; J Neuropathol Exp Neurol. 1995 Nov;54(6):802-11. (PMID: 7595653) ; Mol Med Rep. 2012 Nov;6(5):967-72. (PMID: 22923091) ; Neuroreport. 1993 Jan;4(1):69-72. (PMID: 8453039) ; J Neuroinflammation. 2012 Jan 16;9:8. (PMID: 22248049) ; Neurobiol Aging. 2012 May;33(5):1002.e17-27. (PMID: 22014620) ; Pharmacol Biochem Behav. 2005 Dec;82(4):686-94. (PMID: 16380159) ; Chin Med J (Engl). 2005 Oct 5;118(19):1637-43. (PMID: 16232349) ; Exp Neurol. 2008 Apr;210(2):681-90. (PMID: 18261728) ; Curr Pharm Des. 2010;16(25):2766-78. (PMID: 20698820) ; Int Immunopharmacol. 2010 Jun;10(6):668-78. (PMID: 20347053) ; J Neuroinflammation. 2012 May 29;9:106. (PMID: 22642825) ; Phytomedicine. 2010 Oct;17(12):950-5. (PMID: 20382007) ; Nat Prod Res. 2007 Jun;21(7):600-5. (PMID: 17613817) ; Phytomedicine. 2013 Aug 15;20(11):975-9. (PMID: 23746958) ; J Neuropathol Exp Neurol. 2013 Mar;72(3):178-85. (PMID: 23399896) ; Gen Pharmacol. 1993 Sep;24(5):1063-8. (PMID: 8270163) ; Neuroscience. 2007 Mar 30;145(3):911-22. (PMID: 17321691) ; Curr Urol Rep. 2011 Dec;12(6):470-8. (PMID: 21948222) ; Int Immunopharmacol. 2009 Mar;9(3):360-5. (PMID: 19185062) ; Int Immunopharmacol. 2012 Jan;12(1):74-9. (PMID: 22056950) ; Am J Pathol. 2002 May;160(5):1583-7. (PMID: 12000710) ; Pharmacol Biochem Behav. 2007 May;87(1):130-40. (PMID: 17509675) ; J Clin Invest. 2004 Nov;114(9):1248-59. (PMID: 15520857) ; Nature. 1997 Oct 9;389(6651):603-6. (PMID: 9335500) ; Biol Pharm Bull. 2010;33(8):1307-13. (PMID: 20686223) ; Clin Exp Pharmacol Physiol. 2013 Sep;40(9):635-43. (PMID: 23772748) ; EMBO Rep. 2006 Sep;7(9):940-6. (PMID: 16906128) ; Neurobiol Aging. 1998 Nov-Dec;19(6):527-33. (PMID: 10192211) ; Eur J Pharmacol. 2010 Jan 25;626(2-3):213-8. (PMID: 19782061) ; Neuron. 2002 Aug 1;35(3):419-32. (PMID: 12165466) ; Urology. 2006 Dec;68(6):1350-4. (PMID: 17169663) ; Free Radic Biol Med. 2010 Jan 1;48(1):1-15. (PMID: 19800967) ; Planta Med. 2000 Aug;66(6):575-7. (PMID: 10985091) ; Molecules. 2011 Feb 01;16(2):1336-48. (PMID: 21285919) ; Asian J Androl. 2003 Mar;5(1):15-8. (PMID: 12646997) Substance Nomenclature: 0 (APP protein, human) ; 0 (Amyloid beta-Protein Precursor) ; 0 (Flavonoids) ; 0 (Tgfb1 protein, mouse) ; 0 (Transforming Growth Factor beta1) ; VNM47R2QSQ (icariin) Entry Date(s): Date Created: 20140808 Date Completed: 20151130 Latest Revision: 20211021 Update Code: 20240513 PubMed Central ID: PMC4125230

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.